EPMA Journal

, Volume 8, Issue 4, pp 357–376 | Cite as

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

  • Rostyslav V. BubnovEmail author
  • Lidiia P. Babenko
  • Liudmyla M. Lazarenko
  • Viktoria V. Mokrozub
  • Oleksandr A. Demchenko
  • Oleksiy V. Nechypurenko
  • Mykola Ya. Spivak



Microbiome-modulating interventions are promising for treatment and prevention of metabolic syndrome. The number of probiotic strains demonstrated ability to decrease cholesterol level in vivo, however, it was poorly confirmed in a clinical setting. The aim was to study the effects of L. acidophilus IMV B-7279, L. casei IMV B-7280, B. animalіs VKL and B. animalіs VKB separately and in various compositions on the level of serum cholesterol, gut microbiota contents and liver morphology on a high-calorie-induced obesity model in BALB/c mice.

Materials and methods

We used for the study female BALB/c mice 6–8 weeks old (18–24 g). Experimental animals were fed by a fat-enriched diet (FED), and 8 experimental groups were formed (12 mice in each group) to test strains of probiotic bacteria L. delbrueckii subsp. bulgaricus IMV B-7281, L. casei IMV B-7280, B. animalіs VKL and B. animalіs VKB and compositions. We used ultrasound for in vivo assessment of the liver and visceral (mesenteric) fat size. In the blood serum of the obese mice, the level of cholesterol was estimated. The liver morphology and gut microbiota of obese mice were studied.


We revealed that after treatment with all of the studied probiotic bacteria and compositions of B. animalis VKL/B. animalis VKB/L. casei IMV B-7280, the weight of obese mice decreased, and cholesterol and its fraction levels in serum were reduced. The size of the liver slightly decreased after treatment with L. delbrueckii subsp. bulgaricus IMV B-7281, B. аnimalis VKB or probiotic compositions; we observed reduction of the mesenteric fat size after injection of all these probiotic bacteria (separately) and probiotic compositions. We defined the strain-dependent effects on serum lipid profiles, liver morphology and the gut microbiota. The B. animalis VKL/B. animalis VKB/L. casei IMV B-7280 composition effectively recovered the liver morphological structure of obese mice. The number of Lactobacillus spp., Bifidobacterium spp. and coliform bacteria increased, the number of staphylococci and streptococci reduced, and the number of microscopic fungi significantly decreased in the gut of obese mice after treatment with L. casei IMV B-7280, L. delbrueckii subsp. bulgaricus IMV B-7281, B. animalis (separately) or their compositions.


L. casei IMV B-7280 (separately) and a composition of B. animalis VKL/B. animalis VKB/L. casei IMV B-7280 are effective at decreasing the weight of obese mice, decreasing cholesterol level, restoring the liver morphology and beneficially modulating the gut microbiome in high-calorie-induced obesity.


Predictive preventive personalized medicine Metabolic syndrome Obesity Lactobacillus Bifidobacterium Cholesterol Liver Gut microbiota Mouse model: mesenteric fat Ultrasound 



The study was conducted with the support of the State Agency on Science, Innovations and Informatisation of Ukraine.

Author’s information

RVB, M.D., Ph.D. is a researcher of the Inteferon Department of Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine and a medical doctor in the Clinical Hospital ‘Pheophania’ of the State Affairs Department, and National Representative of the European Association for Predictive, Preventive and Personalized Medicine (EPMA) in Ukraine.

Professor LML, D.Sc., LPB Ph.D., VVM Ph.D., and OVN Ph.D. are researchers in the Inteferon Department of Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine.

OMD Ph.D. is a medical doctor at JSC SPC ‘DiaprofMed’.

Professor MYS, Ph.D., D.Sci. is a corresponding member of the National Academy of Sciences of Ukraine and the director of the Interferon Department of Zabolotny Institute of Microbiology and Virology, NAS of Ukraine.

Authors’ contributions

RVB suggested the idea and design of the study, participated in experiments, did the ultrasound survey, study analysis, prepared the discussion, formulated future outlooks, and performed the second and final article drafting.

LML, LPB and VVM performed the experiments on animals and analysis of the study.

LML and LPB prepared the first draft of the manuscript, did the literature analysis, interpreted the results, and performed the statistical analysis.

OVN did the liver morphology study.

OMD participated in analysis of the study.

MYS did the organization, manuscript revision, data interpretation, and contributed to the overall development of the studied topic.

All authors read and approved the final manuscript.


Not applicable.

Compliance with ethical standards

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

Authors declare that they have no competing interests.


  1. 1.
    WHO: Obesity and overweight: Fact sheet N. 311. Accessed 19 July 2017.
  2. 2.
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375(9710):181–3.
  3. 3.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the west Virginian population. Int J Med Sci. 2016;13(1):25–38.
  5. 5.
    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Ndumele CE, Nasir K, Conceiçao RD, Carvalho JAM, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32.
  7. 7.
    Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14.
  8. 8.
    Gortmaker SL, Swinburn BA, Levy D, Carter R, Mabry PL, Finegood DT, et al. Changing the future of obesity: science, policy, and action. Lancet. 2011;378(9793):838–47.
  9. 9.
    WHO “Cardiovascular Disease,” Fact sheet no. 317, WHO, Geneva, Switzerland, 2009,
  10. 10.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Crit Pathw Cardiol. 2005;4(4):198–203.CrossRefPubMedGoogle Scholar
  11. 11.
    Adachi S. Factors associated with metabolic syndrome that affect prognosis in heart failure patients. Circ J. 2016;80(3):596–7.
  12. 12.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.CrossRefPubMedGoogle Scholar
  13. 13.
    Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213–23.
  14. 14.
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26(1):5–11.
  16. 16.
    Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9.
  17. 17.
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.Google Scholar
  18. 18.
    David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559–63.
  19. 19.
    Bendali F, Kerdouche K, Hamma-Faradji S, Drider D. In vitro and in vivo cholesterol lowering ability of lactobacillus pentosus KF923750. Benefic Microbes. 2017;8(2):271–80.
  20. 20.
    Kondo S, Kamei A, Xiao JZ, Iwatsuki K, Abe K. Bifidobacterium breve B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese mice: a DNA microarray analysis. Benefic Microbes. 2013;3:247–51.
  21. 21.
    Kondo S, Xiao JZ, Satoh T, Odamaki T, Takahashi S, Sugahara H, et al. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem. 2010;74(8):1656–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, et al. Supplementation of lactobacillus curvatus HY7601 and lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One. 2013;8(3):e59470.
  23. 23.
    Huang Y, Wang J, Quan G, Wang X, Yang L, Zhong L. Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinalcholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol. 2014;80(24):7496–504.
  24. 24.
    Wang LX, Liu K, Gao DW, Hao JK. Protective effects of two lactobacillus plantarum strains in hyperlipidemic mice. World J Gastroenterol. 2013;19(20):3150–6.
  25. 25.
    Wang BG, Xu HB, Wei H, Zeng ZL, Xu F. Oral administration of Bifidobacterim bifidum for modulating microflora, acid and bile resistance, and physiological indices in mice. Can J Microbiol. 2015;61(2):155–63.
  26. 26.
    Kim SH, Huh CS, Choi ID, Jeong JW, Ku HK, Ra JH, et al. The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol. 2014;117(3):834–45.
  27. 27.
    Moya-Pérez A, Romo-Vaquero M, Tomás-Barberán F, Sanz Y, García-Conesa MT. Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model of diet-induced obesity. Nutr Metab Cardiovasc Dis. 2014;24(1):57–64.
  28. 28.
    Tian F, Chi F, Wang G, Liu X, Zhang Q, Chen Y, et al. Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcohol-induced liver injury in amouse model of chronic alcohol feeding. J Microbiol. 2015;53(12):856–63.
  29. 29.
    Nido SA, Shituleni SA, Mengistu BM, Liu Y, Khan AZ, Gan F, et al. Effects of selenium-enriched Probiotics on lipid metabolism, Antioxidative status, Histopathological lesions, and related gene expression in mice fed a high-fat diet. Biol Trace Elem Res. 2016;171(2):399–409.
  30. 30.
    Song M, Park S, Lee H, Min B, Jung S, Park S, et al. Effect of lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice. J Dairy Sci. 2015;98(3):1492–501.
  31. 31.
    Wu CC, Weng WL, Lai WL, Tsai HP, Liu WH, Lee MH, et al. Effect of lactobacillus plantarum strain K21 on high-fat diet-fed obese mice. Evid Based Complement Alternat Med. 2015;2015:391767.
  32. 32.
    Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014 Sep 4;513(7516):59–64.
  34. 34.
    Thomas H. NAFLD: a gut microbiome signature for advanced fibrosis diagnosis in NAFLD. Nat Rev Gastroenterol Hepatol. 2017;14(7):388.
  35. 35.
    WHO/FAO Scientific document. Accessed 19 July 2017.
  36. 36.
    Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014(8):506–14.
  37. 37.
    WGO Updates guidelines on probiotics and prebiotics Accessed 28 June 2017.
  38. 38.
    Sung V, Cabana MD, D’Amico F, Deshpande G, Dupont C, Indrio F, et al. Lactobacillus reuteri DSM17938 for managing infant colic: protocol for an individual participant data meta-analysis. BMJ Open. 2014;4(12):e006475.
  39. 39.
    Sanders ME, Merenstein DJ, Ouwehand AC, Reid G, Salminen S, Cabana MD, et al. Probiotic use in at-risk populations. J Amer Pharmacy Assoc. 2016;56:680–6.Google Scholar
  40. 40.
    Reid G, Abrahamsson T, Bailey M, Bindels LB, Bubnov R, Ganguli K, et al. How do probiotics and prebiotics function at distant sites? Benef Microbes. 2017;8(4):521–533.
  41. 41.
    The International Scientific Association for Probiotics and Prebiotics (ISAPP) Meeting Report. Accessed 19 July 2017.
  42. 42.
    Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV. Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA J. 2015;6:14.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Reid G. Quo vadis – EFSA? Benefic Microbes. 2011;2(3):177–81.
  44. 44.
    Mital BK, Garg SK. Anticarcinogenic, hypocholesterolemic, and antagonistic activities of lactobacillus acidophilus. Crit Rev Microbiol. 1995;21(3):175–214.CrossRefPubMedGoogle Scholar
  45. 45.
    Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25(1):41–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Agerbaek M, Gerdes LU, Richelsen B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. Eur J Clin Nutr. 1995;49(5):346–52.Google Scholar
  47. 47.
    Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13(5):278–88.
  48. 48.
    Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering Probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917.
  49. 49.
    Simons LA, Amansec SG, Conway P. Effect of lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis. 2006;16:531–5.CrossRefPubMedGoogle Scholar
  50. 50.
    Park YH, Kim JG, Shin YW, Kim HS, Kim YJ, Chun T, et al. Effects of lactobacillus acidophilus 43121 and a mixture of lactobacillus casei and Bifidobacterium longum on the serum cholesterol level and fecal sterol excretion in hypercholesterolemia-induced pigs. Biosci Biotechnol Biochem. 2008;72:595–600.CrossRefPubMedGoogle Scholar
  51. 51.
    Lye HS, Rahmat-Ali GR, Liong MT. Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int Dairy J. 2010;20:169–75.CrossRefGoogle Scholar
  52. 52.
    Babenko LP, Sokolviak OY, Мokrozub VV, Nechypurenko OO, Demchenko OM, Bubnov RV, et al. Lactobacillus and Bifidobacterium probiotic strains reduce cholesterol levels and affect the gut microbiota in obese mice. United European Gastroenterol J. 2016;4(5S):A374–5.
  53. 53.
    Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M. Meta-analysis: effects of Probiotic supplementation on lipid profiles in normal to mildly Hypercholesterolemic individuals. PLoS One. 2015;10(10):e0139795.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000 Nov;54(11):856–60.CrossRefPubMedGoogle Scholar
  55. 55.
    Aronsson L, Huang Y, Parini P, Korach-André M, Håkansson J, Gustafsson JÅ, et al. Decreased fat storage by lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One. 2010;5(9):e13087.
  56. 56.
    Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008;49(5):821–30.
  57. 57.
    Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21(11):844–50.
  58. 58.
    Cho YA, Kim J. Effect of Probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(43):e1714.
  59. 59.
    Ooi L-G, Liong M-T. Cholesterol-lowering effects of Probiotics and Prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 2010;11(6):2499–522.
  60. 60.
    Greany KA, Bonorden MJ, Hamilton-Reeves JM, McMullen MH, Wangen KE, Phipps WR, et al. Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr. 2008;62:232–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Wang J, Zhang H, Chen X, Chen Y. Menghebilige, Bao Q. Selection of potential probiotic lactobacilli for cholesterol-lowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet. J Dairy Sci. 2012 Apr;95(4):1645–54.CrossRefPubMedGoogle Scholar
  62. 62.
    Sharma S, Puri S, Kurpad AV. Potential of Probiotics in Hypercholesterolemia: A Review of In Vitro and In Vivo Findings. Altern Ther Health Med. 2017;23:7.Google Scholar
  63. 63.
    Lewis SJ, Burmeister S. A double-blind placebo-controlled study of the effects of lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr. 2005 Jun;59(6):776–80.CrossRefPubMedGoogle Scholar
  64. 64.
    O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2:17057.
  65. 65.
    Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol. 2014;87(2):303–14.
  66. 66.
    Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediat Inflamm. 2010;2010.
  67. 67.
    Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011;12(1):5–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Lazarenko LM, Babenko LP, Bubnov RV, Demchenko OM, Zotsenko VM, Boyko NV, et al. Imunobiotics are the novel biotech drugs with antibacterial and Immunomodulatory properties. Mikrobiol Z. 2017;79(1):66–75.Google Scholar
  69. 69.
    Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–68.
  70. 70.
    Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova Tetyana V, Babenko LP, Lazarenko LM, et al. The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J. 2014;5:2.Google Scholar
  71. 71.
    Mokrozub VV, Lazarenko LM, Sichel LM, Bubnov RV, Spivak MY. The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA J. 2015;6:13.CrossRefGoogle Scholar
  72. 72.
    Baron DM, Clerte M, Brouckaert P, Raher MJ, Flynn AW, Zhang H, et al. In vivo noninvasive characterization of brown adipose tissue blood flow by contrast ultrasound in mice. Circ Cardiovasc Imaging. 2012 Sep 1;5(5):652–9.Google Scholar
  73. 73.
    Arora T, Anastasovska J, Gibson G, Tuohy K, Sharma RK, Bell J, et al. Effect of Lactobacillus acidophilus NCDC 13 supplementation on the progression of obesity in diet-induced obese mice. Br J Nutr. 2012;108(8):1382–9.
  74. 74.
    Arora T, Singh S, Sharma RK. Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition. 2013;29(4):591–6.
  75. 75.
    Lumeng CN. Innate immune activation in obesity. Mol Asp Med. 2013;34(1):12–29.
  76. 76.
    Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53(2):100–8.
  77. 77.
    Michael DR, Davies TS, Moss JWE, Calvente DL, Ramji DP, Marchesi JR, et al. The anti-cholesterolaemic effect of a consortium of probiotics: an acute study in C57BL/6J mice. Sci Rep. 2017 Jun 6;7(1):2883.
  78. 78.
    Bosch M, Fuentes MC, Audivert S, Bonachera MA, Peiró S, Cuñé J. Lactobacillus plantarum CECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J Sci Food Agric. 2014;94(4):803–9.
  79. 79.
    Kim G, Lee BH. Biochemical and molecular insights into bile salt hydrolase in the gastrointestinal microflora-a review. Asian Australas J Anim Sci. 2005;18:1505.CrossRefGoogle Scholar
  80. 80.
    Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr. 2012;107(10):1505–13.
  81. 81.
    Xue L, He J, Gao N, Lu X, Li M, Wu X, et al. Probiotics may delay the progression of NAFLD by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:45176.
  82. 82.
    Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Relman diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–8.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Frank DN, Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780–5.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes. 2008;32(11):1720–4.
  85. 85.
    Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11(9):639–47.
  86. 86.
    Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015;9(1):1–15.
  87. 87.
    Stenman LK, Burcelin R, Lahtinen S. Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics. Benefic Microbes. 2016;7(1):11–22.
  88. 88.
    Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benefic Microbes. 2014;5(1):3–17.
  89. 89.
    Cani PD, Knauf C. How gut microbes talk to organs: the role of endocrine and nervous routes. Mol Metab. 2016;5(9):743–52.
  90. 90.
    Chen J, He X, Huang J. Diet effects in gut microbiome and obesity. J Food Sci. 2014;79(4):R442–51.
  91. 91.
    McPhee JB, Schertzer J. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci. 2015;129:1083–96.
  92. 92.
    Fåk F, Bäckhed F. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe−/− mice. PLoS One. 2012;7(10):e46837.
  93. 93.
    Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009 Dec;9(6):737–43.CrossRefPubMedGoogle Scholar
  94. 94.
    Konopelniuk VV, Goloborodko II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al. Efficacy of fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study. EPMA J. 2017.
  95. 95.
    Petschow B, Doré J, Hibberd P, Dinan T, Reid G, Blaser M, et al. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann N Y Acad Sci. 2013;1306:1–17.Google Scholar
  96. 96.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23.
  97. 97.
    Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, preventive and personalised medicine. EPMA J. 2012;3(1):14.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Akhmetov I, Bubnov RV. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? EPMA J. 2017;8:1.
  99. 99.
    Gilbert JA, Quinn RA, Debelius J, Xu ZZ, Morton J, Garg N, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535(7610):94–103.
  100. 100.
    Zmora N, Zeevi D, Korem T, Segal E, Elinav E. Taking it personally: personalized utilization of the human microbiome in health and disease. Cell Host Microbe. 2016;19(1):12–20.
  101. 101.
    Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet. 2016;48(11):1396–406.
  102. 102.
    Bubnov R, Polivka J Jr, Zubor P, Koniczka K, Golubnitschaja O. Pre-metastatic niches in breast cancer: are they created by or prior to the tumour onset? “Flammer syndrome” relevance to address the question. EPMA J. 2017;8:141–57.
  103. 103.
    Most J, Goossens GH, Reijnders D, Canfora EE, Penders J, Blaak EE. Gut microbiota composition strongly correlates to peripheral insulin sensitivity in obese men but not in women. Benefic Microbes. 2017;16:1–6.
  104. 104.
    Wu L, Ma D, Walton-Moss B, He Z. Effects of low-fat diet on serum lipids in premenopausal and postmenopausal women: a meta-analysis of randomized controlled trials. Menopause. 2014 Jan;21(1):89–99.CrossRefPubMedGoogle Scholar
  105. 105.
    Moloney RD, Desbonnet L, Clarke G, Dinan TG, Cryan JF. The microbiome: stress, health and disease. Mamm Genome. 2014;25(1–2):49–74.
  106. 106.
    Cerdá B, Pérez M, Pérez-Santiago JD, Tornero-Aguilera JF, González-Soltero R, Larrosa M. Gut microbiota modification: another piece in the puzzle of the benefits of physical exercise in health? Front Physiol. 2016;7:51.
  107. 107.
    Moiseyenko Y, Sukhorukov V, Pyshnov G, Mankovska I, Rozova K, Miroshnychenko O, et al. Antarctica challenges the new horizons in predictive, preventive, personalized medicine: preliminary results and attractive hypothesis for multi-disciplinary prospective studies in the Ukrainian ‘Akademik Vernadsky’ station. EPMA J. 2016;7(1):11.
  108. 108.
    NY Dynamic Neuromuscular Rehabilitation & Physical Therapy Clinic. Accessed 19 July 2017.
  109. 109.
    Ouwehand AC. A review of dose-responses of probiotics in human studies. Benefic Microbes. 2017;8(2):143–51.
  110. 110.
    Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, et al. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr. 2006 Nov;60(11):1284–93.Google Scholar
  111. 111.
    Heinsen FA, Fangmann D, Müller N, Schulte DM, Rühlemann MC, Türk K, et al. Beneficial effects of a dietary weight loss intervention on human gut microbiome diversity and metabolism are not sustained during weight maintenance. Obes Facts. 2016;9(6):379–91.
  112. 112.
    Zhang C, Li S, Yang L, Huang P, Li W, Wang S, et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun. 2013;4:2163.
  113. 113.
    Shane AL, Cabana M, Vidry S, Merenstein D, Hummelen R, Ellis CL, et al. Guide to designing, conducting, publishing, and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes. 2010;1:243–53.Google Scholar
  114. 114.
    Reid G, Gaudier E, Guarner F, Huffnagle GB, Macklaim JM, Munoz AM, et al. Walter J; international scientific Association for Probiotics and Prebiotics. Responders and non-responders to probiotic interventions: how can we improve the odds? Gut Microbes. 2010;1(3):200–4.
  115. 115.
    Cinti S. The Adipose Organ: Implications For Prevention And Treatment Of Obesity. In M.L. Frelut (Ed.), The ECOG’s eBook on Child and Adolescent Obesity: 2015. Retrieved from Accessed 28 June 2017.
  116. 116.
    Karunatilaka KS, Cameron EA, Martens EC, Koropatkin NM, Biteen JS. Superresolution imaging captures carbohydrate utilization dynamics in human gut symbionts. MBio. 2014 Nov 11;5(6):e02172.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Kim SJ, Park SH, Sin HS, Jang SH, Lee SW, Kim SY, Kwon B, Yu KY, Kim SY, Yang DK. Hypocholesterolemic effects of Probiotic mixture on diet-induced Hypercholesterolemic rats. Nutrients. 2017.
  118. 118.
    Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017.
  119. 119.
    Kobyliak N, Virchenko O, Falalyeyeva T, Kondro M, Beregova T, Bodnar P, et al. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats. Biomed Pharmacother. 2017;90:608–14.
  120. 120.
    Yu I-T, Ju C-C, Lin J, Wu H-L, Yen H-T. Effects of probiotics and selenium combination on the immune and blood cholesterol concentration of pigs. J Anim Feed Sci. 2004;13(4):625–34.
  121. 121.
    EFSA NDA. Panel (EFSA panel on dietetic products, nutrition and allergies), 2016. General scientific guidance for stakeholders on health claim applications. EFSA J. 2016;14(1):4367.
  122. 122.
    Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9.

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2017

Authors and Affiliations

  • Rostyslav V. Bubnov
    • 1
    • 2
    Email author
  • Lidiia P. Babenko
    • 1
  • Liudmyla M. Lazarenko
    • 1
  • Viktoria V. Mokrozub
    • 1
  • Oleksandr A. Demchenko
    • 1
  • Oleksiy V. Nechypurenko
    • 1
  • Mykola Ya. Spivak
    • 1
    • 3
  1. 1.Zabolotny Institute of Microbiology and VirologyNational Academy of Sciences of UkraineKyivUkraine
  2. 2.Clinical Hospital ‘Pheophania’ of State Affairs DepartmentKyivUkraine
  3. 3.LCL ‘DIAPROF’KyivUkraine

Personalised recommendations